Mangoceuticals, Inc.

MGRX Healthcare Health Information Services

Mangoceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $456,000.00, down 26.0% from fiscal 2024. In the quarter to June 2026, revenue fell 59.1%, EPS grew 84.2% and free cash flow grew 79.3%, each against the same quarter a year earlier.

0.30 0.02 −6.25%
Market cap
$7.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
3/9
Altman Z
−2.14
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 3 3
ROE
(136.16%) (141.66%) (113.90%) (95.09%)
ROA
(126.56%) (131.23%) (106.11%) (86.27%)
ROIC
(78.16%) (82.19%) (77.92%) (62.76%)
Return on Tangible Assets
9,711.81% (3,134.38%) 3,668.22% 1,312.11%
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.51) (0.58) (0.30) (0.23)
Free Cash Flow
(5.90) (5.85) (4.89) (3.89)
Other line items
Cash ROIC
(36.41%) (35.06%) (35.80%) (30.51%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.29 0.33 0.23 0.17
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
1,046.55 739.76 980.12 2,276.67
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
3,807.69% 3,666.97% 4,014.69% 3,954.90%
Share Based Compensation of Revenue
2,373.50% 2,350.15% 2,259.36% 1,989.28%
Interest Coverage
212.07 (174.23) (141.49) (32.89)
Operating CF/Net income
0.30 0.28 0.25 0.26
Depreciation/Fixed assets
766.80 1,646.72 1,893.80 1,768.69
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.04 0.05 0.03 0.02
Operating CF per Share
(0.51) (0.58) (0.30) (0.23)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated 2 Oct 2026